VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
VolitionRx Limited to Attend Conferences in December
Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies
